Cytomegalovirus News and Research RSS Feed - Cytomegalovirus News and Research

Cytomegalovirus (CMV) is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella-zoster virus (which causes chickenpox), and Epstein-Barr virus (which causes infectious mononucleosis). Infection with CMV is a major cause of disease and death in immunocompromised patients, including organ transplant recipients, patients undergoing hemodialysis, patients with cancer, patients receiving immunosuppressive drugs, and HIV-infected patients. While drugs are available for treatment of these conditions, the primary drug choices carry significant side effects and warnings. Currently, there are no anti-CMV drugs indicated for treatment of primary CMV infection during pregnancy resulting in infections that can have catastrophic consequences to the newborn. Maternal-fetal transfer of CMV infection results in a fetal death rate of 12% and most survivors have permanent debilitating disorders, including mental retardation, vision loss, and sensorineural deafness.
Reducing amyloid fibril levels in semen may help reduce transmission of HIV

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

There may be two new ways to fight AIDS -- using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
Study: Chickenpox vaccination increases incidence of shingles in younger adults

Study: Chickenpox vaccination increases incidence of shingles in younger adults

Vaccinating one-year-olds against chickenpox could temporarily nearly double the incidence of shingles in the wider population, but in younger adults than previously thought. [More]
Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round. [More]
Latent CMV infection induces telomere shortening

Latent CMV infection induces telomere shortening

The telomeres are repetitive DNA sequences at each end of our chromosomes. Studies show that in every cell division, the telomere is shortened. As a result, the telomere limits the cell to a fixed number of divisions and a limited life span. An essential part of human cells they affect how our cells age - as people with longer telomeres live longer lives. Surprisingly, people who are infected with a latent virus, that is, an asymptomatic virus, have shorter telomeres. [More]
Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter Diagnostics supports IFCC-EFLM EuroMedLab 2015 with a showcase of solutions to improve workflow for the diagnostics laboratory. Held from 22-24 June 2015 at the Paris Palais des Congrès France, the company demonstrates its dedication to moving the clinical diagnostic lab forward with its total laboratory solution—from automation, chemistry, immunoassay and haematology to microbiology and its new molecular diagnostics system. [More]
UCL-led team develops new technique to find resistant TB faster

UCL-led team develops new technique to find resistant TB faster

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. [More]
Scientists discover molecular switch that ‘turns off’ HCMV

Scientists discover molecular switch that ‘turns off’ HCMV

Human cytomegalovirus (HCMV) is an extremely common virus, which as other members of the herpes virus family causes life-long infections in humans. Most individuals are exposed to HCMV during childhood, yet symptoms can be easily fought off by a healthy immune system. [More]
CMV-based vaccine provides long-lasting protective immunity against Ebola virus

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations. [More]
Scientists identify key molecules that trigger immune system to fight tularemia

Scientists identify key molecules that trigger immune system to fight tularemia

Research led by scientists at St. Jude Children's Research Hospital has identified key molecules that trigger the immune system to launch an attack on the bacterium that causes tularemia. [More]
Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes. [More]
Study describes the dual role of microRNA during hepatitis C infection

Study describes the dual role of microRNA during hepatitis C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery. [More]
Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers. [More]
Babies treated for CMV infection for six months have better developmental outcomes

Babies treated for CMV infection for six months have better developmental outcomes

Babies treated for symptomatic cytomegalovirus (CMV) infection for six months, instead of the standard six weeks, have better hearing and developmental outcomes, according to a new study from the University of Alabama at Birmingham. [More]
Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Bone marrow transplantation is a life-saving therapy for patients with blood cancers like leukemia or lymphoma. However, the depletion of the patient's immune system prior to transplantation can put patients at risk of for an infection by a virus called cytomegalovirus (CMV) that can be life threatening in these immune-compromised individuals. [More]

Ganciclovir drug resistance may occur more frequently in cystic fibrosis patients

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation. [More]
SLU investigators find promising candidates for new herpes virus treatments

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments. [More]

CF patients require close monitoring for resistance to ganciclovir after lung transplantation

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
Researchers awarded grant to develop non-invasive device to detect Human Cytomegalovirus

Researchers awarded grant to develop non-invasive device to detect Human Cytomegalovirus

Researchers from Cardiff and Swansea Universities have been awarded a grant of more than £323k to develop a new, non-invasive, low-cost, and easy to use point of care device to diagnose Human Cytomegalovirus (HCMV). [More]
First three recipients of inaugural Harry Winston Fellowships named

First three recipients of inaugural Harry Winston Fellowships named

Harry Winston, Inc. and the UCLA Children's Discovery and Innovation Institute have named the first three recipients of the inaugural Harry Winston Fellowships. [More]
Advertisement
Advertisement